ANI Pharma (ANIP) Misses Q4 EPS by 10c, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020
February 27, 2020 8:30 AM ESTBAUDETTE, Minn., Feb. 27, 2020 /PRNewswire/ --
For the full year ended December 31, 2019:
Record net revenues of $206.5 million, an increase of 2.5% versus 2018 GAAP net income of $6.1 million and diluted GAAP earnings per share of $0.50 Adjusted non-GAAP EBITDA of $83.2 million Adjusted non-GAAP diluted earnings per share of $5.06For the fourth quarter 2019:
Net revenues of $48.0 million versus $57.1 million in 2018 GAAP net loss of $4.8 million and diluted GAAP loss per share of $0.41 Adjusted non-GAAP EBITDA of $17.4 million... More